Breakthrough T1D – Mechanisms of Graft Acceptance in Clinical Islet Transplantation
Event details
| Date | 17.09.2024 |
| Category | Call for proposal |
Aim: RFA seeks to support research utilising existing clinical datasets to expand understanding of mechanisms contributing to long term survival/function and immune tolerance toward transplanted islet grafts to treat T1D. Relevant datasets may include National Institutes of Health NIDDK Central Repository studies, CIT02 through CIT08, pan-CIT, and Collaborative Islet Transplant Registry samples/data, or center specific datasets from national islet transplant programmes and registries, and clinical trials. Industry sponsored trials and/or trials using alternative sources of insulin producing cells (e.g. human stem cell-derived islets or porcine sources) are also of interest.
Examples of topics pertinent to this call include, but are not limited to:
Duration: 2 years
Eligibility: Applications may be submitted by domestic (US) and foreign non-profit organizations and public and private entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and, where relevant, eligible agencies of the federal government.
Applicants must hold an MD, DMD, DVM, PhD, or equivalent degree, and hold a faculty position or equivalent at a college, university, medical school or other research facility. There are no citizenship requirements
How to Apply: Applicants should submit an LOI, [2 pages maximum] online via RMS360 to be considered for a full proposal request. The LOI template provided on the RMS360 website must be used to complete the application to be considered for a full proposal request.
Deadline:
Examples of topics pertinent to this call include, but are not limited to:
- Using clinical datasets to identify biomarkers/signatures of beta cell stress or immune rejection to better measure and predict graft failure prior to decline in c-peptide and/or glycemic control.
- Single cell profiling of immune cells from patients undergoing islet transplantation as correlates of therapeutic outcomes, ideally with longitudinal sampling.
- Analysis of immune populations in clinical datasets testing alternative immune protection strategies such as immunomodulatory therapy.
- High dimensional -omic profiling of banked serum or blood samples from islet transplant recipients as correlates of therapeutic outcomes.
- Investigating common signals within other transplant types, such as liver or kidney, which exhibit immune tolerance that may apply to islet transplant.
Duration: 2 years
Eligibility: Applications may be submitted by domestic (US) and foreign non-profit organizations and public and private entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and, where relevant, eligible agencies of the federal government.
Applicants must hold an MD, DMD, DVM, PhD, or equivalent degree, and hold a faculty position or equivalent at a college, university, medical school or other research facility. There are no citizenship requirements
How to Apply: Applicants should submit an LOI, [2 pages maximum] online via RMS360 to be considered for a full proposal request. The LOI template provided on the RMS360 website must be used to complete the application to be considered for a full proposal request.
Deadline:
- Letter of Intent: 17 September 2024 (outcome notification: 24 September)
- Full proposal: 22 October 2024
- More information about the call is available here.
- The proposal should be submitted on the online portal RMS360.
- For any other questions, please contact the Research Office.
Practical information
- Informed public
- Free